<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02341911</url>
  </required_header>
  <id_info>
    <org_study_id>Fudan BR2015-16</org_study_id>
    <nct_id>NCT02341911</nct_id>
  </id_info>
  <brief_title>Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)</brief_title>
  <acronym>TNBC</acronym>
  <official_title>A Phase II, Single-center, Open-Label, Randomized Study of Gemcitabine Plus Cisplatin (GP) Versus Gemcitabine Plus Carboplatin (GC) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast
      Cancer (TNBC)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase II, Single-center, Open-Label, Randomized Study of Gemcitabine Plus Cisplatin (GP)
      Versus Gemcitabine Plus Carboplatin (GC) as First-Line Treatment in Patients With Advanced
      Triple-Negative Breast Cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS (Progression Free Survival)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine,cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GP (gemcitabine and cisplatin combination)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine,carboplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GC (gemcitabine and carboplatin combination)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine,cisplatin</intervention_name>
    <description>Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1</description>
    <arm_group_label>Gemcitabine,cisplatin</arm_group_label>
    <other_name>experimental arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine,carboplatin</intervention_name>
    <description>Gemcitabine 1000 mg/m2, IV drip 30 minutes, D1, D8 Carboplatin AUC 2, IV drip 120 minutes, D1</description>
    <arm_group_label>Gemcitabine,carboplatin</arm_group_label>
    <other_name>control arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological proven unresectable recurrent or advanced breast cancer, including de
             novo stage IV disease.

          2. Triple-negative for estrogen receptor (ER), progestogen receptor (PR), and human
             epithelial receptor-2 (HER2) by immunohistochemistry (ER &lt;1%, PR &lt;1% and Her2
             negative). A negative Her2 gene amplification should be verified by FISH test for
             those patients with Her2 (2+). For those with Her2 (1+), FISH test might be considered
             by the investigator.

          3. No prior chemotherapy for metastatic breast cancer is permitted. Prior administration
             of chemotherapy in the adjuvant/neoadjuvant setting is acceptable if completed 6
             months before the enrollment.

          4. At least one measurable disease according to the response evaluation criteria in solid
             tumor (RECIST 1.1)

          5. Performance status no more than 1

          6. All patients enrolled are required to have adequate hematologic, hepatic, and renal
             function

          7. Life expectancy longer than 12 weeks

          8. No serious medical history of heart, lung, liver and kidney

          9. Be able to understand the study procedures and sign informed consent.

         10. Patients with good compliance

        Exclusion Criteria:

          1. Pregnant or lactating women (female patients of child-bearing potential must have a
             negative serum pregnancy test within 14 days before the first day of drug dosing, or,
             if positive, a pregnancy should be ruled out by ultrasound)

          2. Women of child-bearing potential, unwilling to use adequate contraceptive protection
             during the process of the study

          3. Treatment with radiotherapy at the axial skeleton within 4 weeks before the first
             treatment or has not recovered from all toxicities of previous radiotherapy

          4. Treatment with an investigational product within 4 weeks before the first treatment

          5. Patients with symptomatic central nervous system metastases are not permitted, except
             for those with stable and asymptomatic brain metastases who have completed cranial
             irradiation, and have at least one measurable lesion outside the brain. Radiotherapy
             should be completed within 4 weeks prior to the registration

          6. Other active malignancies (including other hematologic malignancies) or other
             malignancies within the last 5 years, except for cured nonmelanoma skin cancer or
             cervical intraepithelial neoplasia.

          7. Patients having a history of clinically significant cardiovascular, hepatic,
             respiratory or renal diseases, clinically significant hematological and endocrinal
             abnormalities, clinically significant neurological or psychiatric conditions

          8. Uncontrolled serious infection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xichun Hu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xichun Hu, MD, PhD</last_name>
    <phone>64175590</phone>
    <phone_ext>5006</phone_ext>
    <email>huxicun@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Biyun Wang, MD</last_name>
    <phone>64175590</phone>
    <phone_ext>5000</phone_ext>
    <email>pro_wangbiyun@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xichun Hu, MD,PhD</last_name>
      <phone>64175590</phone>
      <phone_ext>5006</phone_ext>
      <email>huxicun@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Biyun Wang, MD</last_name>
      <phone>64175590</phone>
      <phone_ext>5000</phone_ext>
      <email>pro_wangbiyun@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2015</study_first_submitted>
  <study_first_submitted_qc>January 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2015</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xichun Hu</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>triple negative breast cancer</keyword>
  <keyword>fine line chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

